1. Home
  2. ESTA vs MESO Comparison

ESTA vs MESO Comparison

Compare ESTA & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Establishment Labs Holdings Inc.

ESTA

Establishment Labs Holdings Inc.

HOLD

Current Price

$70.68

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$17.88

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESTA
MESO
Founded
2004
2004
Country
Costa Rica
Australia
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.8B
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
ESTA
MESO
Price
$70.68
$17.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
2
Target Price
$68.29
$24.00
AVG Volume (30 Days)
517.5K
192.5K
Earning Date
11-05-2025
08-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$190,973,000.00
$17,198,000.00
Revenue This Year
$29.25
$465.44
Revenue Next Year
$24.94
$75.37
P/E Ratio
N/A
N/A
Revenue Growth
24.76
191.39
52 Week Low
$26.56
$9.61
52 Week High
$73.19
$22.00

Technical Indicators

Market Signals
Indicator
ESTA
MESO
Relative Strength Index (RSI) 69.18 63.71
Support Level $62.77 $16.43
Resistance Level $69.69 $17.65
Average True Range (ATR) 3.22 0.64
MACD -0.43 0.28
Stochastic Oscillator 77.82 93.38

Price Performance

Historical Comparison
ESTA
MESO

About ESTA Establishment Labs Holdings Inc.

Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: